The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization
Open accessAbstract
Liposomes are widely utilized as a carrier to improve therapeutic efficacy of agents thanks to their merits of high loading capacity, targeting delivery, reliable protection of agents, good biocompatibility, versatile structure modification and adjustable characteristics, such as size, surface charge, membrane flexibility and the agent loading mode. In particular, in recent years, through modification with immunopotentiators and targeting molecules, and in combination with innovative immunization devices, liposomes are rapidly developed as a multifunctional vaccine adjuvant-delivery system (VADS) that has a high capability in inducing desired immunoresponses, as they can target immune cells and even cellular organelles, engender lysosome escape, and promote Ag cross-presentation, thus enormously enhancing vaccination efficacy. Moreover, after decades of development, several products developed on liposome VADS have already been authorized for clinical immunization and are showing great advantages over conventional vaccines. This article describes in depth some critical issues relevant to the development of liposomes as a VADS, including principles underlying immunization, physicochemical properties of liposomes as the immunity-influencing factors, functional material modification to enhance immunostimulatory functions, the state-of-the-art liposome VADSs, as well as the marketed vaccines based on a liposome VADS. Therefore, this article provides a comprehensive reference to the development of novel liposome vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“Also, as a VADS, liposomes are suitable for making the vaccines that are adaptive to various administration routes, such as intramuscular and subcutaneous injection, oral uptake, intranasal and other topical ways [23].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1×
“Fifth, the prevalence of low reproducibility of the currently published outcomes, especially, in drug development field [168], resulted from the inappropriate designs with little practical rationality combined with the positive result-oriented publishing bias and the misconception of “research for publication” [169],…”
BackgroundPathogen Recognition by the Innate Immune System
Kumar, H., Kawai, T., & Akira, S. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2010.529976 · Cited by 2,257
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“Whilst the adaptive immune system has evolved for around 500 million years and is confined to vertebrates, the innate immune system has been established for a much longer time and acts as the main defensive strategy among vertebrates, invertebrates, as well as in plants, under modulation by rather conserved mechanisms…”
BackgroundLiposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
The generation of antibody-secreting plasma cells
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3795 · Cited by 1,454
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Immunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Systematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 938
Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei
NUSSENZWEIG, R. S., VANDERBERG, J., MOST, H., & ORTON, C. (1967) · Nature · doi:10.1038/216160a0 · Cited by 937
Autoimmunity and the Clearance of Dead Cells
Nagata, S., Hanayama, R., & Kawane, K. (2010) · Cell · doi:10.1016/j.cell.2010.02.014 · Cited by 890
Novel applications of liposomes
Lasic, D. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01220-7 · Cited by 867
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
Liposomes as immunological adjuvants
ALLISON, A. C., & GREGORIADIS, G. (1974) · Nature · doi:10.1038/252252a0 · Cited by 675
Verhoven, B., Schlegel, R. A., & Williamson, P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1597 · Cited by 666
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Freeman, G. J., Casasnovas, J. M., Umetsu, D. T., & DeKruyff, R. H. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00903.x · Cited by 614
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
Casella, C. R., & Mitchell, T. C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8228-6 · Cited by 560
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
Phospholipid spherules (liposomes) as a model for biological membranes
Sessa, G., & Weissmann, G. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43097-4 · Cited by 446
Martin, M. D., & Badovinac, V. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02692 · Cited by 436
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Immunological notes. XVII–XXIV
Glenny, A. T., Pope, C. G., Waddington, H., & Wallace, U. (1926) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700290106 · Cited by 399
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
HogenEsch, H., O’Hagan, D. T., & Fox, C. B. (2018) · npj Vaccines · doi:10.1038/s41541-018-0089-x · Cited by 391
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Antigen-Presenting Cells in the Skin
Kashem, S. W., Haniffa, M., & Kaplan, D. H. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052215 · Cited by 361
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 354
The development of vaccines: how the past led to the future
Plotkin, S. A., & Plotkin, S. L. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2668 · Cited by 333
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., & Bramwell, V. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.036 · Cited by 333
Werninghaus, K., Babiak, A., Groß, O., Hölscher, C., Dietrich, H., Agger, E. M., Mages, J., Mocsai, A., Schoenen, H., Finger, K., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081445 · Cited by 315
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010) · Journal of Clinical Virology · doi:10.1016/s1386-6532(10)70002-0 · Cited by 313
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Biomaterials for Nanoparticle Vaccine Delivery Systems
Sahdev, P., Ochyl, L. J., & Moon, J. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1419-y · Cited by 310
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Accelerating Next-Generation Vaccine Development for Global Disease Prevention
Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K., & Plotkin, S. A. (2013) · Science · doi:10.1126/science.1232910 · Cited by 282
The influence of temperature, cholesterol content and pH on liposome stability
Sułkowski, W. W., Pentak, D., Nowak, K., & Sułkowska, A. (2005) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2004.11.075 · Cited by 280
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Hem, S. L., & HogenEsch, H. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.685 · Cited by 264
A model for the packing of lipids in bilayer membranes
Israelachvili, J. N., & Mitchell, D. J. (1975) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(75)90381-8 · Cited by 263
The effect of physical barriers and properties on the oral absorption of particulates
Norris, D. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00037-4 · Cited by 262
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
Plotkin, S. A. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00290-09 · Cited by 256
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Vasilakos, J. P., & Tomai, M. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811208 · Cited by 254
Seifert, M., & Küppers, R. (2016) · Leukemia · doi:10.1038/leu.2016.226 · Cited by 249
Control of Lipid Membrane Stability by Cholesterol Content
Raffy, S., & Teissié, J. (1999) · Biophysical Journal · doi:10.1016/s0006-3495(99)77363-7 · Cited by 245
Immune system targeting by biodegradable nanoparticles for cancer vaccines
Silva, J. M., Videira, M., Gaspar, R., Préat, V., & Florindo, H. F. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.010 · Cited by 233
Mohanan, D., Slütter, B., Henriksen-Lacey, M., Jiskoot, W., Bouwstra, J. A., Perrie, Y., Kündig, T. M., Gander, B., & Johansen, P. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.012 · Cited by 229
Vaccination in the elderly: an immunological perspective
Chen, W. H., Kozlovsky, B. F., Effros, R. B., Grubeck-Loebenstein, B., Edelman, R., & Sztein, M. B. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.05.002 · Cited by 228
Aluminum Vaccine Adjuvants: Are they Safe?
Tomljenovic, L., & A. Shaw, C. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795933740 · Cited by 211
Hoffmann, P. R., Kench, J. A., Vondracek, A., Kruk, E., Daleke, D. L., Jordan, M., Marrack, P., Henson, P. M., & Fadok, V. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1393 · Cited by 210
From empiricism to rational design: a personal perspective of the evolution of vaccine development
De Gregorio, E., & Rappuoli, R. (2014) · Nature Reviews Immunology · doi:10.1038/nri3694 · Cited by 204
Recent Advances in Peptide-Based Subunit Nanovaccines
Skwarczynski, M., & Toth, I. (2014) · Nanomedicine · doi:10.2217/nnm.14.187 · Cited by 203
Phosphatidylserine receptors: Enhancers of enveloped virus entry and infection
Moller-Tank, S., & Maury, W. (2014) · Virology · doi:10.1016/j.virol.2014.09.009 · Cited by 188
Henriksen‐Lacey, M., Christensen, D., Bramwell, V. W., Lindenstrøm, T., Agger, E. M., Andersen, P. L., & Perrie, Y. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.027 · Cited by 175
Vaccinology: past achievements, present roadblocks and future promises
ANDRE, F. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00702-8 · Cited by 173
Antigen Presentation to B Cells
Heesters, B. A., van der Poel, C. E., Das, A., & Carroll, M. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.10.003 · Cited by 172
Akira, S. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0106 · Cited by 170
Influenza virosomes as a vaccine adjuvant and carrier system
Moser, C., Amacker, M., & Zurbriggen, R. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.15 · Cited by 169
AS03- and MF59-Adjuvanted Influenza Vaccines in Children
Wilkins, A. L., Kazmin, D. A., Napolitani, G., Clutterbuck, E., Pulendran, B., Siegrist, C., & Pollard, A. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01760 · Cited by 167
Mann, J. F. S., Shakir, E., Carter, K. C., Mullen, A. B., Alexander, J., & Ferro, V. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.040 · Cited by 166
Vaccines for preventing herpes zoster in older adults
Gagliardi, A. M., Andriolo, B. N., Torloni, M. R., & Soares, B. G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008858.pub3 · Cited by 166
New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells
Kimura, H., Caturegli, P., Takahashi, M., & Suzuki, K. (2015) · Journal of Immunology Research · doi:10.1155/2015/541984 · Cited by 162
Shakweh, M., Besnard, M., Nicolas, V., & Fattal, E. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.04.006 · Cited by 161 · cited 1×
“Also, in a previous report researchers confirmed in mice that both anionic and neutral NPs showed a higher affinity to the Peyer's patches than cationic particles [87], suggesting the negatively charged carriers may favour oral and, possibly, other mucosal vaccination.”
BackgroundCell and fluid sampling microneedle patches for monitoring skin-resident immunity
Mandal, A., Boopathy, A. V., Lam, L. K. W., Moynihan, K. D., Welch, M. E., Bennett, N. R., Turvey, M. E., Thai, N., Van, J. H., Love, J. C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar2227 · Cited by 158
Lipid Vesicle Size Determines the Th1 or Th2 Response to Entrapped Antigen
Brewer, J. M., Tetley, L., Richmond, J. A., et al. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4000 · Cited by 154
Influenza virosomes as vaccine adjuvant and carrier system
Moser, C., Müller, M., Kaeser, M. D., Weydemann, U., & Amacker, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811195 · Cited by 150
Dendouga, N., Fochesato, M., Lockman, L., Mossman, S. P., & Giannini, S. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.088 · Cited by 149
Designing liposomal adjuvants for the next generation of vaccines
Perrie, Y., Crofts, F., Devitt, A., Griffiths, H. R., Kastner, E., & Nadella, V. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.005 · Cited by 140
Zhang, W., Wang, L., Liu, Y., Chen, X., Liu, Q., Jia, J., Yang, T., Qiu, S., & Ma, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.022 · Cited by 139
T cell–independent B cell activation induces immunosuppressive sialylated IgG antibodies
Heß, C., Winkler, A., Lorenz, A. K., Holecska, V., Blanchard, V., Eiglmeier, S., Schoen, A.-L., Bitterling, J., Stoehr, A. D., Petzold, D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65938 · Cited by 136
Vesicle Size Influences the Trafficking, Processing, and Presentation of Antigens in Lipid Vesicles
Brewer, J. M., Pollock, K. G. J., Tetley, L., & Russell, D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6143 · Cited by 135
Bielinska, A. U., Janczak, K. W., Landers, J. J., Makidon, P. E., Sower, L. E., Peterson, J. W., & Baker, J. R. (2007) · Infection and Immunity · doi:10.1128/iai.00070-07 · Cited by 135
Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation
Yadav, S. C., Kumari, A., & Yadav, R. (2010) · Peptides · doi:10.1016/j.peptides.2010.10.003 · Cited by 132
Moignic, A. L., Malard, V., Benvegnu, T. J., Lemiègre, L., Berchel, M., Jaffrès, P., Baillou, C., Guillot‐Delost, M., Macedo, R., Rochefort, J., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.035 · Cited by 130
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine
James, S. F., Chahine, E. B., Sucher, A. J., & Hanna, C. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018758431 · Cited by 126
Vaccine adjuvants : preparation methods and research protocols
O’Hagan, D. T. (2000) · Humana Press eBooks · Cited by 124
Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
Alving, C. R., Rao, M., Steers, N. J., Matyas, G. R., & Mayorov, A. V. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.35 · Cited by 122
Entrapment of proteins in liposomes prevents allergic reactions in pre‐immunised mice
Gregoriadis, G. C., & ALLISON, A. C. (1974) · FEBS Letters · doi:10.1016/0014-5793(74)80813-6 · Cited by 120
Editorial: Drug Delivery: Too Much Complexity, Not Enough Reproducibility?
Leroux, J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709002 · Cited by 120
Henriksen‐Lacey, M., Devitt, A., & Perrie, Y. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.05.019 · Cited by 118
Christensen, D., Henriksen‐Lacey, M., Kamath, A. T., Lindenstrøm, T., Korsholm, K. S., Christensen, J. P., Rochat, A., Lambert, P., Andersen, P. L., Siegrist, C., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.016 · Cited by 113
Shi, Y., & Rock, K. L. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200201)32:1<155::aid-immu155>3.0.co;2-p · Cited by 111
Liposomal adjuvants for human vaccines
Alving, C. R., Beck, Z., Matyas, G. R., & Rao, M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1151871 · Cited by 108
Orr, M. T., Fox, C. B., Baldwin, S. L., Sivananthan, S. J., Lucas, E., Lin, S. X., Phan, T., Moon, J. J., Vedvick, T. S., Reed, S. G., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.030 · Cited by 106
Vaccines and the Future of Human Immunology
Germain, R. N. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.014 · Cited by 106
Liposomes as Immunological Adjuvants
ALLISON, A. C., & Gregoriadis, G. (1976) · Springer eBooks · doi:10.1007/978-3-642-81049-7_8 · Cited by 104
Liu, L., Ma, P., Wang, H., Zhang, C., Sun, H., Wang, C., Song, C. X., Leng, X., Kong, D., & Ma, G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.050 · Cited by 103
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Syed, Y. Y. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0603-x · Cited by 101
Liposomes as immunological adjuvants and vaccine carriers
Gregoriadis, G., Gürsel, İ., Gürsel, M., & McCormack, B. (1996) · Journal of Controlled Release · doi:10.1016/0168-3659(96)01355-7 · Cited by 100
Hanson, M. C., Abraham, W. D., Crespo, M. P., Chen, S. H., Liu, H., Szeto, G. L., Kim, M., Reinherz, E. L., & Irvine, D. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.045 · Cited by 94
Guiding Principles in the Design of Molecular Bioconjugates for Vaccine Applications
Liu, H., & Irvine, D. J. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00103 · Cited by 94
Adjuvant strategies to improve vaccination of the elderly population
Weinberger, B. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.014 · Cited by 94
Wang, N., Wang, T., Zhang, M., Chen, R., Niu, R., & Deng, Y. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.04.007 · Cited by 88
Self-citationWang, T., Zhen, Y., Ma, X., Wei, B., Li, S., & Wang, N. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.01.005 · Cited by 87
Self-citationCD4+ Memory T Cells at Home in the Tissue: Mechanisms for Health and Disease
Schreiner, D., & King, C. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02394 · Cited by 87
Schmidt, S., Khadke, S., Korsholm, K. S., Perrie, Y., Rades, T., Andersen, P. L., Foged, C., & Christensen, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.034 · Cited by 80
Tokatlian, T., Kulp, D. W., Mutafyan, A. A., Jones, C. A., Menis, S., Georgeson, E., Kubitz, M., Zhang, M. H., Melo, M. B., Silva, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34853-2 · Cited by 78
Jakobsche, C. E., Parker, C. G., Tao, R. N., Kolesnikova, M. D., Douglass, E. F., & Spiegel, D. A. (2013) · ACS Chemical Biology · doi:10.1021/cb4004942 · Cited by 77
No publication without confirmation
Mogil, J. S., & Macleod, M. R. (2017) · Nature · doi:10.1038/542409a · Cited by 77
Oberoi, H. S., Yorgensen, Y. M., Morasse, A., Evans, J. T., & Burkhart, D. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.006 · Cited by 76
Zhen, Y., Wang, N., Gao, Z., Ma, X., Wei, B., Deng, Y., & Wang, T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.081 · Cited by 70
Self-citationDevelopment of liposomal amphotericin B formulation
Gulati, M., Bajad, S. U., Singh, S., Ferdous, A. J., & Singh, M. S. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006844 · Cited by 69
Kaur, R., Bramwell, V. W., Kirby, D. J., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.012 · Cited by 67
Wang, N., Zhen, Y., Jin, Y., Wang, X., Li, N., Jiang, S., & Wang, T. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.009 · Cited by 66
Self-citationAdvances in HIV-1 Vaccine Development
Gao, Y., McKay, P. F., & Mann, J. F. S. (2018) · Viruses · doi:10.3390/v10040167 · Cited by 64
Biological feasibility and importance of a gonorrhea vaccine for global public health
Vincent, L. R., & Jerse, A. E. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.081 · Cited by 61
Liposome research in drug delivery: The early days
Gregoriadis, G. (2008) · Journal of drug targeting · doi:10.1080/10611860802228350 · Cited by 60
Arigita, C., Bevaart, L., Everse, L. A., Koning, G. A., Hennink, W. E., Crommelin, D. J. A., van de Winkel, J. G. J., van Vugt, M. J., Kersten, G. F. A., & Jiskoot, W. (2003) · Infection and Immunity · doi:10.1128/iai.71.9.5210-5218.2003 · Cited by 58
Hassane, F. S., Phalipon, A., Tanguy, M., Guerreiro, C., Belot, F., Frisch, B., Mulard, L. A., & Schuber, F. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.031 · Cited by 57
Barnier-Quer, C., Elsharkawy, A., Romeijn, S. G., Kros, A., & Jiskoot, W. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030392 · Cited by 57
Nanoparticles for immune system targeting
Du, J., Zhang, Y. S., Hobson, D., & Hydbring, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.013 · Cited by 57
Karmakar, P. S., Lee, K., Sarkar, S., Wall, K. A., & Sucheck, S. J. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00528 · Cited by 55
Bagalkot, V., Deiuliis, J. A., Rajagopalan, S., & Maiseyeu, A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.009 · Cited by 55
Liposomes Came First: The Early History of Liposomology
Weissig, V. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6591-5_1 · Cited by 55
Rincón-Restrepo, M., Mayer, A. T., Hauert, S., Bonner, D. K., Phelps, E. A., Hubbell, J. A., Swartz, M. A., & Hirosue, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.047 · Cited by 55
Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen
Vangala, A., Bramwell, V. W., McNeil, S., et al. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.01.010 · Cited by 54
Phospholipid Bilayer-Coated Aluminum Nanoparticles as an Effective Vaccine Adjuvant-Delivery System
Wang, T., Zhen, Y., Ma, X., Wei, B., & Wang, N. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00348 · Cited by 52
Self-citationBeck, Z., Torres, O. B., Matyas, G. R., Lanar, D. E., & Alving, C. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.006 · Cited by 51
Negatively Charged Liposomes Show Potent Adjuvant Activity When Simply Admixed with Protein Antigens
Yanasarn, N., Sloat, B. R., & Cui, Z. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200016d · Cited by 49
Biotech giant publishes failures to confirm high-profile science
Baker, M. (2016) · Nature · doi:10.1038/nature.2016.19269 · Cited by 47
B Cells use Conserved Polarity Cues to Regulate Their Antigen Processing and Presentation Functions
Yuseff, M.-I., & Lennon‐Duménil, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00251 · Cited by 41
Vaccine design: emerging concepts and renewed optimism
Grimm, S. K., & Ackerman, M. E. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.015 · Cited by 41
Review of intranasal influenza vaccine
Glueck, R. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00174-0 · Cited by 39
Omilusik, K. D., & Goldrath, A. W. (2017) · Nature · doi:10.1038/d41586-017-08280-8 · Cited by 38
Abhyankar, M. M., Orr, M. T., Lin, S. X., Suraju, M. O., Simpson, A., Blust, M., Pham, T., Guderian, J. A., Tomai, M. A., Elvecrog, J., et al. (2018) · npj Vaccines · doi:10.1038/s41541-018-0060-x · Cited by 37
Viral subversion of B cell responses within secondary lymphoid organs
Kuka, M., & Iannacone, M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.133 · Cited by 35
Wasan, E. K., Syeda, J., Strom, S., Cawthray, J. F., Hancock, R. E. W., Wasan, K. M., & Gerdts, V. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.01.058 · Cited by 32
Macrophage reprogramming by negatively charged membrane phospholipids controls infection
Cauvi, D. M., Hawisher, D., Dores-Silva, P. R., Lizardo, R. E., & Maio, A. D. (2018) · The FASEB Journal · doi:10.1096/fj.201801579r · Cited by 27
Wilkinson, A., Lattmann, E., Roces, C. B., Pedersen, G. K., Christensen, D., & Perrie, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.002 · Cited by 26
Recent Developments in nanocarrier-aided Mucosal Vaccination
Kammona, O., Bourganis, V., Karamanidou, T., & Kiparissides, C. A. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0015 · Cited by 25
Jacoberger-Foissac, C., Saliba, H., Seguin, C., Brion, A., Kakhi, Z., Frisch, B., Fournel, S., & Heurtault, B. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.002 · Cited by 24
Chopra, A., & Cevc, G. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.01.006 · Cited by 23
Schneider, J. L., & Balu‐Iyer, S. V. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.06.018 · Cited by 23
Yotsumoto, S., Kakiuchi, T., & Aramaki, Y. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.05.037 · Cited by 21
Orbegozo-Medina, R. A., Martínez‐Sernández, V., González–Warleta, M., Castro-Hermida, J. A., Mezo, M., & Ubeira, F. M. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.115 · Cited by 21
Wang, T., & Wang, N. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150923100147 · Cited by 20
Self-citationWang, X., Wang, N., Li, N., Zhen, Y., & Wang, T. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1158368 · Cited by 17
Self-citationMolinos-Albert, L. M., Bilbao, E., Agulló, L., Marfil, S., García, E., de la Concepción, M. L. R., Izquierdo‐Useros, N., Vilaplana, C., Nieto‐Garai, J. A., Contreras, F. ‐., et al. (2017) · Scientific Reports · doi:10.1038/srep40800 · Cited by 15
Kirby, D. J., Kaur, R., Agger, E. M., Andersen, P. L., Bramwell, V. W., & Perrie, Y. (2013) · Current Drug Delivery · doi:10.2174/1567201811310030003 · Cited by 9
Sarnquist, C., Holubar, M. K., García‐García, L., Ferreyra-Reyes, L. D., Delgado-Sánchez, G., Cruz‐Hervert, L. P., Montero-Campos, R., Altamirano, J., Purington, N., Boyle, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy606 · Cited by 9
Cited by
Liu, P., Chen, G., & Zhang, J. (2022) · Molecules · doi:10.3390/molecules27041372 · Cited by 1,334
“, SUVs with a size of less than 200 nm and LUVs with a size of 200–500 nm [34].”
BackgroundChitosan Derivatives and Their Application in Biomedicine
Wang, W., Meng, Q., Li, Q., Liu, J., Zhou, M., Jin, Z., & Zhao, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020487 · Cited by 982
The role of liposomes in clinical nanomedicine development. What now? Now what?
Crommelin, D. J. A., van Hoogevest, P., & Storm, G. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.023 · Cited by 349
Andra, V. V. S. N. L., Pammi, S. V. N., Bhatraju, L. V. K. P., & Ruddaraju, L. K. (2022) · BioNanoScience · doi:10.1007/s12668-022-00941-x · Cited by 316
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
Metadata
- Authors
- Wang, N., Chen, M., & Wang, T.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 303
- Pages
- 130-150
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2942812484
- Cited by
- 308
- References
- 152
- FWCI
- 10.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.